Category: 199522-66-2

On December 12, 2000, Ankersen, Michael; Stidsen, Carsten Enggaard; Crider, Michael Albert published a patent.Quality Control of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine The title of the patent was Use of pyridinylaminoalkyl- and imidazolylalkyl-substituted thioureas, isothioureas, and guanidines as somatostatin agonists and antagonists, for treating diseases related to the eye. And the patent contained the following:

The invention relates to the use of somatostatin receptor ligands of nonpeptide origin, e.g., I or II, or a pharmaceutically acceptable salt thereof [wherein: m = 2, 3, 4, 5 or 6; n = 1, 2 or 3; p = 1, 2, 3, 4, 5 or 6; R1, R2 = independently H or C1-6 alkyl optionally substituted with halo, amino, OH, alkoxy, or aryl; X = S, O, NH, NCOPh or N(CN); A = (hetero)aryl optionally substituted with halo, amino, OH, NO2, C1-6 alkyl, C1-6 alkoxy, or aryl, B = (hetero)aryl optionally substituted with halo, amino, OH, C1-6 alkyl, C1-6 alkoxy, or aryl; D = (hetero)aryl or amino, optionally substituted with halo, amino, OH, C1-6 alkyl, C1-6 alkoxy, or aryl]. The compounds have high and/or selective affinity to the somatostatin receptor protein designated SSTR4, and are useful for the preparation of medicaments for treatment of diseases associated with adverse conditions of the retina and/or iris-ciliary body in mammals (no data). Such conditions include high intraocular pressure (IOP) and/or deep ocular infections. The diseases which may be treated are, e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract, and conjunctivitis. Over 40 compounds are claimed for usage, and 27 synthetic examples are given. For instance, propane-1,3-diamine underwent a sequence of: (1) N-arylation with 2-bromopyridine (76%); (2) N-benzylation with NaH and 4-bromobenzyl bromide in DMSO (70%); (3) conversion of the N’-amine to an isothiocyanate using DCC and CS2 (88%); (4) amination of the isothiocyanate with 3-[1-(triphenylmethyl)imidazol-4-yl]propylamine (80%); and (5) deprotection of the trityl group with aqueous HCl in EtOH (99%), to give title compound III.2HCl. The experimental process involved the reaction of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine(cas: 199522-66-2).Quality Control of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine

The Article related to thiourea isothiourea guanidine pyridinylaminoalkyl imidazolylalkyl preparation somatostatin agonist antagonist, antiglaucoma somatostatin receptor agonist antagonist thiourea isothiourea guanidine preparation and other aspects.Quality Control of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On December 12, 2000, Ankersen, Michael; Stidsen, Carsten Enggaard; Crider, Michael Albert published a patent.Quality Control of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine The title of the patent was Use of pyridinylaminoalkyl- and imidazolylalkyl-substituted thioureas, isothioureas, and guanidines as somatostatin agonists and antagonists, for treating diseases related to the eye. And the patent contained the following:

The invention relates to the use of somatostatin receptor ligands of nonpeptide origin, e.g., I or II, or a pharmaceutically acceptable salt thereof [wherein: m = 2, 3, 4, 5 or 6; n = 1, 2 or 3; p = 1, 2, 3, 4, 5 or 6; R1, R2 = independently H or C1-6 alkyl optionally substituted with halo, amino, OH, alkoxy, or aryl; X = S, O, NH, NCOPh or N(CN); A = (hetero)aryl optionally substituted with halo, amino, OH, NO2, C1-6 alkyl, C1-6 alkoxy, or aryl, B = (hetero)aryl optionally substituted with halo, amino, OH, C1-6 alkyl, C1-6 alkoxy, or aryl; D = (hetero)aryl or amino, optionally substituted with halo, amino, OH, C1-6 alkyl, C1-6 alkoxy, or aryl]. The compounds have high and/or selective affinity to the somatostatin receptor protein designated SSTR4, and are useful for the preparation of medicaments for treatment of diseases associated with adverse conditions of the retina and/or iris-ciliary body in mammals (no data). Such conditions include high intraocular pressure (IOP) and/or deep ocular infections. The diseases which may be treated are, e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract, and conjunctivitis. Over 40 compounds are claimed for usage, and 27 synthetic examples are given. For instance, propane-1,3-diamine underwent a sequence of: (1) N-arylation with 2-bromopyridine (76%); (2) N-benzylation with NaH and 4-bromobenzyl bromide in DMSO (70%); (3) conversion of the N’-amine to an isothiocyanate using DCC and CS2 (88%); (4) amination of the isothiocyanate with 3-[1-(triphenylmethyl)imidazol-4-yl]propylamine (80%); and (5) deprotection of the trityl group with aqueous HCl in EtOH (99%), to give title compound III.2HCl. The experimental process involved the reaction of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine(cas: 199522-66-2).Quality Control of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine

The Article related to thiourea isothiourea guanidine pyridinylaminoalkyl imidazolylalkyl preparation somatostatin agonist antagonist, antiglaucoma somatostatin receptor agonist antagonist thiourea isothiourea guanidine preparation and other aspects.Quality Control of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On May 7, 1998, Ankersen, Michael; Dorwald, Florenzio Zaragoza; Stidsen, Carsten Enggaard; Crider, Albert Michael published a patent.Product Details of 199522-66-2 The title of the patent was Preparation of thiourea derivatives and related compounds as constrained somatostatin agonists and antagonists. And the patent contained the following:

The title compounds B(CH2)nNA(CH2)mYNR1C(:X)E [I; A = (un)substituted aryl; B = (un)substituted aryl; E = heterocyclyl, amino; R1 = H, (un)substituted C1-6 alkyl; X = S, O, NR3; R3 = H, COPh, cyano; Y = bond, etc.; m = 0-6; n = 0-3], somatostatin agonists and antagonists (no data) useful for treating medical disorders related to binding to human somatostatin receptor subtypes, and their pharmaceutically acceptable salts were prepared and claimed. For example, amination of 2,5-dibromopyridine with H2NCH2CH2NH2 in pyridine gave N-1-(5-bromopyrid-2-yl)ethane-1,2-diamine which was benzylated with 3,4-dichlorobenzyl chloride in DMSO in the presence of NaH and the product condensed with CS2 in the presence of dicyclohexylcarbodiimide in THF to give 2-[N-(5-bromopyrid-2-yl)-N-(3,4-dichlorobenzyl)]aminoethyl isothiocyanate. Addition of the latter with 4-[4(5)-imidazolyl]piperidine-2HCl in THF in the presence of Et3N gave a title compound I. The experimental process involved the reaction of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine(cas: 199522-66-2).Product Details of 199522-66-2

The Article related to thiourea derivative preparation somatostatin agonist, imidazolylpiperidinecarbothioic acid bromopyridinyldichlorobenzylaminoethylamide, ethanediamine amination dibromopyridine somatostatin agonist preparation, bromopyridylethanediamine preparation benzylation dichlorobenzyl chloride and other aspects.Product Details of 199522-66-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On December 30, 1998, Ankersen, Michael; Stidsen, Carsten Enggaard; Crider, Michael Albert published a patent.Application of 199522-66-2 The title of the patent was Preparation of thioureas as somatostatin agonists and antagonists for treating diseases related to the eye. And the patent contained the following:

The title compounds [I; m = 2-6; n = 1-3; p = 1-6; R1, R2 = H, (un)substituted C1-6 alkyl; X = S, O, NH, NCOPh, N(CN); A, B, D = (un)substituted aryl, heteroaryl], somatostatin receptor ligands of nonpeptide origin which have high and/or selective affinity to the somatostatin receptor protein designated SSTR4 (no data), and are useful for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal such as high intraocular pressure (IOP) and/or deep ocular infections, were prepared and formulated. The diseases which may be treated with compounds I are e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis. Compounds I are effective at 0.001-50 mg/kg/day. E.g., a 5-step synthesis of II.2HCl, starting with propane-1,3-diamine and 2-bromopyridine, is described. The experimental process involved the reaction of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine(cas: 199522-66-2).Application of 199522-66-2

The Article related to thiourea preparation formulation somatostatin agonist antagonist, glaucoma thiourea preparation formulation, eye disease thiourea preparation formulation, keratitis thiourea preparation formulation, iritis thiourea preparation formulation, retinitis thiourea preparation formulation, cataract thiourea preparation formulation and other aspects.Application of 199522-66-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On May 7, 1998, Ankersen, Michael; Dorwald, Florenzio Zaragoza; Stidsen, Carsten Enggaard; Crider, Albert Michael published a patent.Product Details of 199522-66-2 The title of the patent was Preparation of thiourea derivatives and related compounds as constrained somatostatin agonists and antagonists. And the patent contained the following:

The title compounds B(CH2)nNA(CH2)mYNR1C(:X)E [I; A = (un)substituted aryl; B = (un)substituted aryl; E = heterocyclyl, amino; R1 = H, (un)substituted C1-6 alkyl; X = S, O, NR3; R3 = H, COPh, cyano; Y = bond, etc.; m = 0-6; n = 0-3], somatostatin agonists and antagonists (no data) useful for treating medical disorders related to binding to human somatostatin receptor subtypes, and their pharmaceutically acceptable salts were prepared and claimed. For example, amination of 2,5-dibromopyridine with H2NCH2CH2NH2 in pyridine gave N-1-(5-bromopyrid-2-yl)ethane-1,2-diamine which was benzylated with 3,4-dichlorobenzyl chloride in DMSO in the presence of NaH and the product condensed with CS2 in the presence of dicyclohexylcarbodiimide in THF to give 2-[N-(5-bromopyrid-2-yl)-N-(3,4-dichlorobenzyl)]aminoethyl isothiocyanate. Addition of the latter with 4-[4(5)-imidazolyl]piperidine-2HCl in THF in the presence of Et3N gave a title compound I. The experimental process involved the reaction of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine(cas: 199522-66-2).Product Details of 199522-66-2

The Article related to thiourea derivative preparation somatostatin agonist, imidazolylpiperidinecarbothioic acid bromopyridinyldichlorobenzylaminoethylamide, ethanediamine amination dibromopyridine somatostatin agonist preparation, bromopyridylethanediamine preparation benzylation dichlorobenzyl chloride and other aspects.Product Details of 199522-66-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On December 30, 1998, Ankersen, Michael; Stidsen, Carsten Enggaard; Crider, Michael Albert published a patent.Application of 199522-66-2 The title of the patent was Preparation of thioureas as somatostatin agonists and antagonists for treating diseases related to the eye. And the patent contained the following:

The title compounds [I; m = 2-6; n = 1-3; p = 1-6; R1, R2 = H, (un)substituted C1-6 alkyl; X = S, O, NH, NCOPh, N(CN); A, B, D = (un)substituted aryl, heteroaryl], somatostatin receptor ligands of nonpeptide origin which have high and/or selective affinity to the somatostatin receptor protein designated SSTR4 (no data), and are useful for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal such as high intraocular pressure (IOP) and/or deep ocular infections, were prepared and formulated. The diseases which may be treated with compounds I are e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis. Compounds I are effective at 0.001-50 mg/kg/day. E.g., a 5-step synthesis of II.2HCl, starting with propane-1,3-diamine and 2-bromopyridine, is described. The experimental process involved the reaction of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine(cas: 199522-66-2).Application of 199522-66-2

The Article related to thiourea preparation formulation somatostatin agonist antagonist, glaucoma thiourea preparation formulation, eye disease thiourea preparation formulation, keratitis thiourea preparation formulation, iritis thiourea preparation formulation, retinitis thiourea preparation formulation, cataract thiourea preparation formulation and other aspects.Application of 199522-66-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem